BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 31812697)

  • 1. The covalent CDK7 inhibitor THZ1 enhances temsirolimus-induced cytotoxicity via autophagy suppression in human renal cell carcinoma.
    Chow PM; Liu SH; Chang YW; Kuo KL; Lin WC; Huang KH
    Cancer Lett; 2020 Feb; 471():27-37. PubMed ID: 31812697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer.
    Wang J; Zhang R; Lin Z; Zhang S; Chen Y; Tang J; Hong J; Zhou X; Zong Y; Xu Y; Meng R; Xu S; Liu L; Zhang T; Yang K; Dong X; Wu G
    J Hematol Oncol; 2020 Jul; 13(1):99. PubMed ID: 32690037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of Angiogenesis by Targeting Cyclin-Dependent Kinase 7 in Human Umbilical Vein Endothelial Cells and Renal Cell Carcinoma: An In Vitro and In Vivo Study.
    Shi CS; Kuo KL; Chen MS; Chow PM; Liu SH; Chang YW; Lin WC; Liao SM; Hsu CH; Hsu FS; Chang HC; Huang KH
    Cells; 2019 Nov; 8(11):. PubMed ID: 31752390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDK7 inhibition by THZ1 suppresses cancer stemness in both chemonaïve and chemoresistant urothelial carcinoma via the hedgehog signaling pathway.
    Chow PM; Chang YW; Kuo KL; Lin WC; Liu SH; Huang KH
    Cancer Lett; 2021 Jun; 507():70-79. PubMed ID: 33741425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDK7 Inhibition is Effective in all the Subtypes of Breast Cancer: Determinants of Response and Synergy with EGFR Inhibition.
    McDermott MSJ; Sharko AC; Munie J; Kassler S; Melendez T; Lim CU; Broude EV
    Cells; 2020 Mar; 9(3):. PubMed ID: 32155786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Covalent CDK7 Inhibitor THZ1 Potently Induces Apoptosis in Multiple Myeloma Cells
    Zhang Y; Zhou L; Bandyopadhyay D; Sharma K; Allen AJ; Kmieciak M; Grant S
    Clin Cancer Res; 2019 Oct; 25(20):6195-6205. PubMed ID: 31358538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDK7 blockade suppresses super-enhancer-associated oncogenes in bladder cancer.
    Yang Y; Jiang D; Zhou Z; Xiong H; Yang X; Peng G; Xia W; Wang S; Lei H; Zhao J; Qian Z; Wu S; Pang J
    Cell Oncol (Dordr); 2021 Aug; 44(4):871-887. PubMed ID: 33905040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2/BCL-XL inhibitor ABT-263.
    Huang T; Ding X; Xu G; Chen G; Cao Y; Peng C; Shen S; Lv Y; Wang L; Zou X
    Cell Death Dis; 2019 Aug; 10(8):602. PubMed ID: 31399555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of cyclin-dependent kinase 7 suppresses human hepatocellular carcinoma by inducing apoptosis.
    Zhong L; Yang S; Jia Y; Lei K
    J Cell Biochem; 2018 Dec; 119(12):9742-9751. PubMed ID: 30145799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. THZ1 targeting CDK7 suppresses c-KIT transcriptional activity in gastrointestinal stromal tumours.
    Sun J; Zhang Q; Sun X; Xue A; Gao X; Shen K
    Cell Commun Signal; 2022 Sep; 20(1):138. PubMed ID: 36076237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanomaterial-Facilitated Cyclin-Dependent Kinase 7 Inhibition Suppresses Gallbladder Cancer Progression via Targeting Transcriptional Addiction.
    Huang CS; Xu QC; Dai C; Wang L; Tien YC; Li F; Su Q; Huang XT; Wu J; Zhao W; Yin XY
    ACS Nano; 2021 Sep; 15(9):14744-14755. PubMed ID: 34405985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. THZ1 reveals CDK7-dependent transcriptional addictions in pancreatic cancer.
    Lu P; Geng J; Zhang L; Wang Y; Niu N; Fang Y; Liu F; Shi J; Zhang ZG; Sun YW; Wang LW; Tang Y; Xue J
    Oncogene; 2019 May; 38(20):3932-3945. PubMed ID: 30692639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combinational therapeutic targeting of BRD4 and CDK7 synergistically induces anticancer effects in head and neck squamous cell carcinoma.
    Zhang W; Ge H; Jiang Y; Huang R; Wu Y; Wang D; Guo S; Li S; Wang Y; Jiang H; Cheng J
    Cancer Lett; 2020 Jan; 469():510-523. PubMed ID: 31765738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts.
    Ingels A; Zhao H; Thong AE; Saar M; Valta MP; Nolley R; Santos J; Peehl DM
    Int J Cancer; 2014 May; 134(10):2322-9. PubMed ID: 24243565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. THZ1 suppresses human non-small-cell lung cancer cells in vitro through interference with cancer metabolism.
    Cheng ZJ; Miao DL; Su QY; Tang XL; Wang XL; Deng LB; Shi HD; Xin HB
    Acta Pharmacol Sin; 2019 Jun; 40(6):814-822. PubMed ID: 30446732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer.
    Kim J; Cho YJ; Ryu JY; Hwang I; Han HD; Ahn HJ; Kim WY; Cho H; Chung JY; Hewitt SM; Kim JH; Kim BG; Bae DS; Choi CH; Lee JW
    Gynecol Oncol; 2020 Jan; 156(1):211-221. PubMed ID: 31776040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers.
    Sun B; Mason S; Wilson RC; Hazard SE; Wang Y; Fang R; Wang Q; Yeh ES; Yang M; Roberts TM; Zhao JJ; Wang Q
    Oncogene; 2020 Jan; 39(1):50-63. PubMed ID: 31462705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
    von Roemeling CA; Marlow LA; Wei JJ; Cooper SJ; Caulfield TR; Wu K; Tan WW; Tun HW; Copland JA
    Clin Cancer Res; 2013 May; 19(9):2368-80. PubMed ID: 23633458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors.
    Cayrol F; Praditsuktavorn P; Fernando TM; Kwiatkowski N; Marullo R; Calvo-Vidal MN; Phillip J; Pera B; Yang SN; Takpradit K; Roman L; Gaudiano M; Crescenzo R; Ruan J; Inghirami G; Zhang T; Cremaschi G; Gray NS; Cerchietti L
    Nat Commun; 2017 Jan; 8():14290. PubMed ID: 28134252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels.
    Mahalingam D; Medina EC; Esquivel JA; Espitia CM; Smith S; Oberheu K; Swords R; Kelly KR; Mita MM; Mita AC; Carew JS; Giles FJ; Nawrocki ST
    Clin Cancer Res; 2010 Jan; 16(1):141-53. PubMed ID: 20028765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.